| Literature DB >> 34395935 |
Kyoichi Kihara1, Kazushi Hara1, Ken Sugezawa1, Chihiro Uejima1, Akimitsu Tanio1, Yoichiro Tada1, Manabu Yamamoto1, Hisashi Noma2, Naruro Tokuyasu1, Teruhisa Sakamoto1, Soichiro Honjo1, Yoshiyuki Fujiwara1.
Abstract
OBJECTIVES: Fusobacterium nucleatum, which is the predominant subgingival microbial species found in chronic periodontitis, has been recently proposed as a risk factor for both the initiation and progression of colorectal cancer. We evaluated whether the number of teeth, which represents oral health, is a marker for the prognosis of patients with colorectal cancer.Entities:
Keywords: Fusobacterium nucleatum; colorectal cancer; periodontitis; prognostic factor; tooth number
Year: 2021 PMID: 34395935 PMCID: PMC8321593 DOI: 10.23922/jarc.2020-091
Source DB: PubMed Journal: J Anus Rectum Colon ISSN: 2432-3853
Figure 1.Flow chart showing the cohort of the current study.
Patient and Tumor Characteristics According to the Number of Teeth.
| Number of teeth |
| ||
|---|---|---|---|
| Group A | Group B | ||
| Age (median, range, years) | 67 (39–89) | 78 (56–92) | 0.000* |
| Sex | 0.495 | ||
| Male | 45 (49.5%) | 48 (54.5%) | |
| Female | 46 (50.5%) | 40 (45.5%) | |
| BMI (median, IQR, kg/m2) | 22.7 (21.1-25.3) | 21.5 (19.5-24.2) | 0.193 |
| ECOG PS | 0.000* | ||
| 0 or 1 | 78 (85.7%) | 47 (53.4%) | |
| 2–4 | 13 (14.3%) | 41 (46.6%) | |
| Smoking (missing = 4) | 0.296 | ||
| Never | 59 (67.8%) | 53 (60.2%) | |
| Once or current | 28 (32.2%) | 35 (39.8%) | |
| Charlson comorbidity index (mean) | 2.58 | 2.83 | 0.253 |
| Serum albumin level (median, IQR, g/dL) | 4.1 (3.8-4.4) | 3.9 (3.5-4.1) | 0.000* |
| Serum CEA level (missing = 12. Median, IQR, ng/mL) | 3.0 (1.9-5.8) | 3.3 (2.2-6.7) | 0.392 |
| Serum CA19-9 level (missing =14. Median, IQR, U/mL) | 13.0 (8.8-25.0) | 14.0 (8.0-25.0) | 0.543 |
| Primary tumor sidedness | 0.525 | ||
| Right | 31 (34.1%) | 34 (38.6%) | |
| Left (including rectum) | 60 (65.9%) | 54 (61.4%) | |
| T stage | 0.059 | ||
| 0–2 | 37 (40.7%) | 24 (27.3%) | |
| 3–4 | 54 (59.3%) | 64 (72.7%) | |
| Nodal metastases | 0.248 | ||
| Negative | 60 (65.9%) | 65 (73.9%) | |
| Positive | 31 (34.1%) | 23 (26.1%) | |
| Stage | 0.139 | ||
| 0 | 8 (8.8%) | 5 (5.7%) | |
| I | 24 (26.4%) | 18 (20.5%) | |
| II | 28 (30.8%) | 42 (47.7%) | |
| III | 31 (34.1%) | 23 (26.1%) | |
|
| 0.450 | ||
| Wild type | 39 (52.0%) | 47 (58.0%) | |
| Mutated | 36 (48.0%) | 34 (42.0%) | |
| Adjuvant chemotherapy | 0.530 | ||
| No | 58 (63.7%) | 60 (68.2%) | |
| Yes | 33 (36.3%) | 28 (31.8%) | |
BMI = body mass index; IQR = interquartile range; ECOG PS = Eastern Cooperative Oncology Group Performance Status; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen
*p < 0.05
Figure 2.Survival according to the number of teeth.
(a) Overall survival (n = 179; p = 0.002); (b) CRC-specific survival (n = 179; p = 0.032) in patients who underwent primary tumor resection with curative intent.
Factors Associated with Overall Survival and Cancer-Specific Survival after Primary Tumor Resection.
| Univariable | ||||||
|---|---|---|---|---|---|---|
| Overall survival | Colorectal cancer-specific survival | |||||
| HR | 95% CI |
| HR | 95% CI |
| |
| Age (years) | ||||||
| <70 | Ref. | Ref. | ||||
| ≥70 | 2.597 | 1.022–6.579 | 0.045* | 3.731 | 1.053-13.333 | 0.041* |
| Sex | ||||||
| Male | Ref. | Ref. | ||||
| Female | 0.234 | 0.079-0.687 | 0.008* | 0.280 | 0.079-0.992 | 0.049* |
| ECOG PS | ||||||
| 0 or 1 | Ref. | Ref. | ||||
| 2–4 | 4.831 | 2.096-11.111 | 0.000* | 4.367 | 1.567-12.195 | 0.005* |
| Smoking | ||||||
| Never | Ref. | Ref. | ||||
| Once or current | 1.527 | 0.673-3.460 | 0.311 | 0.602 | 0.192-1.894 | 0.386 |
| Charlson comorbidity index | ||||||
| <4 | Ref. | Ref. | ||||
| ≥4 | 3.401 | 1.326-8.696 | 0.011* | 2.597 | 0.726-9.346 | 0.142 |
| Number of teeth | ||||||
| ≥20 (Group A) | Ref. | Ref. | ||||
| <20 (Group B) | 4.227 | 1.569-11.388 | 0.004* | 3.253 | 1.036-10.219 | 0.043* |
| Serum albumin level (g/dL) | ||||||
| ≥4.1 | Ref. | Ref. | ||||
| <4.1 | 3.961 | 1.347-11.644 | 0.012* | 3.341 | 0.943-11.840 | 0.062 |
| Serum CEA level (ng/mL) | ||||||
| <5.0 | Ref. | Ref. | ||||
| ≥5.0 | 2.439 | 1.025-5.814 | 0.044* | 3.215 | 1.074-9.615 | 0.037* |
| Serum CA19-9 level (U/mL) | ||||||
| ≤37.0 | Ref. | Ref | ||||
| >37.0 | 1.764 | 0.639-4.854 | 0.274 | 2.058 | 0.642-6.579 | 0.225 |
| Primary tumor sidedness | ||||||
| Left (including rectum) | Ref. | Ref. | ||||
| Right | 1.421 | 0.622-3.243 | 0.404 | 2.114 | 0.765-5.837 | 0.149 |
| T stage | ||||||
| 0–2 | Ref. | Ref. | ||||
| 3–4 | 12.987 | 1.745-100.000 | 0.012* | 41.667 | 0.543-∞ | 0.092 |
| Nodal metastases | ||||||
| Negative | Ref. | Ref. | ||||
| Positive | 2.070 | 0.912-4.695 | 0.082 | 1.980 | 0.717-5.464 | 0.187 |
| Adjuvant chemotherapy | ||||||
| No | Ref. | Ref. | ||||
| Yes | 0.635 | 0.262-1.536 | 0.313 | 0.370 | 0.048-2.841 | 0.339 |
ECOG PS = Eastern Cooperative Oncology Group Performance Status; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen; HR = hazard ratio; CI = confidence interval; Ref. = reference
*p < 0.05
Figure 3.Scatter diagram comparing patient age and the number of teeth.
Pearson’s correlation coefficient and the coefficient of determination were −0.542 and 0.294 (p = 0.000), respectively.
Figure 4.Subgroup analyses for overall survival.
HR = hazard ratio; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group Performance Status; CCI = Charlson comorbidity index; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen; NA = not available
Multivariable Analysis of Factors that Were Significantly Different in the Patient Characteristics According to the Number of Teeth for Overall Survival and Colorectal Cancer-Specific Survival.
| Multivariable | ||||||
|---|---|---|---|---|---|---|
| Overall survival | Colorectal cancer-specific survival | |||||
| HR | 95% CI |
| HR | 95% CI |
| |
| Age (years) | ||||||
| <70 | Ref. | Ref. | ||||
| ≥70 | 1.590 | 0.431–5.869 | 0.487 | 1.435 | 0.302-6.803 | 0.649 |
| ECOG PS | ||||||
| 0 or 1 | Ref. | Ref. | ||||
| 2–4 | 3.984 | 1.267-12.500 | 0.018* | 2.639 | 0.772-9.009 | 0.122 |
| Number of teeth | ||||||
| ≥20 (Group A) | Ref. | Ref. | ||||
| <20 (Group B) | 2.983 | 1.025-8.681 | 0.045* | 2.029 | 0.596-6.907 | 0.258 |
| Serum albumin level (g/dL) | ||||||
| ≥4.1 | Ref. | Ref. | ||||
| <4.1 | 2.836 | 0.941-8.546 | 0.064 | 2.379 | 0.654-8.661 | 0.189 |
ECOG PS = Eastern Cooperative Oncology Group Performance Status; HR = hazard ratio; CI = confidence interval; Ref. = reference
*p < 0.05
Patient and Tumor Characteristics According to the Number of Teeth before and after IPW.
| Before IPW | After IPW | |||||
|---|---|---|---|---|---|---|
| Percentage | SMD | Percentage | SMD | |||
| Group A | Group B | Group A | Group B | |||
| Age (years) | −0.8548* | 0.0096 | ||||
| <70 | 61.5 | 22.7 | 41.6 | 42.1 | ||
| ≥70 | 38.5 | 77.3 | 58.4 | 57.9 | ||
| Sex | 0.1021* | 0.0466 | ||||
| Male | 49.5 | 54.5 | 49.8 | 52.1 | ||
| Female | 50.5 | 45.5 | 50.2 | 47.9 | ||
| ECOG PS | -0.7498* | 0.0630 | ||||
| 0 or 1 | 85.7 | 53.4 | 66.4 | 69.3 | ||
| 2–4 | 14.3 | 46.6 | 33.6 | 30.7 | ||
| Smoking | -0.1586* | -0.0280 | ||||
| Never | 67.8 | 60.2 | 63.8 | 62.4 | ||
| Once or current | 32.2 | 39.8 | 36.2 | 37.6 | ||
| Charlson comorbidity index | -0.3347* | -0.0019 | ||||
| <4 | 91.2 | 79.5 | 85.6 | 85.5 | ||
| ≥4 | 8.8 | 20.5 | 14.4 | 14.5 | ||
| Serum albumin level (g/dL) | -0.3853* | -0.0663 | ||||
| ≥4.1 | 51.6 | 33.0 | 43.8 | 40.5 | ||
| <4.1 | 48.4 | 67.0 | 56.2 | 59.5 | ||
| Serum CEA level (ng/mL) | -0.1855* | 0.0688 | ||||
| <5.0 | 69.8 | 61.0 | 64.4 | 67.7 | ||
| ≥5.0 | 30.2 | 39.0 | 35.6 | 32.3 | ||
| Serum CA19-9 level (U/mL) | 0.1665* | -0.0803 | ||||
| ≤37.0 | 83.1 | 88.9 | 85.9 | 83.0 | – | |
| >37.0 | 16.9 | 11.1 | 14.1 | 17.0 | ||
| Primary tumor sidedness | 0.0951 | -0.0263 | ||||
| Left (including rectum) | 65.9 | 61.4 | 64.5 | 65.7 | ||
| Right | 34.1 | 38.6 | 35.5 | 34.3 | ||
| T stage | 0.2855* | 0.0745 | ||||
| 0–2 | 40.7 | 27.3 | 31.6 | 35.1 | ||
| 3–4 | 59.3 | 72.7 | 68.4 | 64.9 | ||
| Nodal metastases | 0.1735* | 0.1021* | ||||
| Negative | 65.9 | 73.9 | 66.6 | 71.4 | ||
| Positive | 34.1 | 26.1 | 33.4 | 28.6 | ||
| Adjuvant chemotherapy | 0.0939 | -0.0270 | ||||
| No | 53.7 | 58.2 | 67.5 | 66.3 | ||
| Yes | 36.3 | 31.8 | 32.5 | 33.7 | ||
IPW = inverse probability weighting; SMD = standardized mean difference; ECOG PS = Eastern Cooperative Oncology Group Performance Status; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen
*|standardized mean difference| > 0.1
Univariable Analysis of the Number of Teeth for Overall Survival and Colorectal Cancer-Specific Survival after IPW.
| Overall survival | Colorectal cancer-specific survival | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Number of teeth | ||||||
| ≥20 (Group A) | Ref. | Ref. | ||||
| <20 (Group B) | 3.297 | 1.107–9.823 | 0.032 | 2.323 | 0.677–7.968 | 0.180 |
HR = hazard ratio; CI = confidence interval; Ref. = reference